ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Idorsia Pharmaceuticals and Simcere Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Idorsia PharmaceuticalsSimcere Pharmaceutical Group
studies on the registry10382
open to participants now315
phase 3 studies under way25
reach primary completion within a year26
programswith a study of their own in two years416

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseIdorsia PharmaceuticalsSimcere Pharmaceutical Group
Phase 100%

Simcere Pharmaceutical Group: 9 of its 16 programs at phase 1

  1. dose expansion of SIM0609 in GC/GEJC cohortphase 1
  2. SIM0388phase 1
  3. SIM0518phase 1
  4. SIM0532phase 1
  5. SIM0609phase 1

and 4 more — sign in to see them all

56%
Phase 2

Idorsia Pharmaceuticals: 1 of its 4 programs at phase 2

  1. ACT-777991phase 2
25%

Simcere Pharmaceutical Group: 1 of its 16 programs at phase 2

  1. SIM0278phase 2
6%
Phase 3

Idorsia Pharmaceuticals: 2 of its 4 programs at phase 3

  1. migalastatphase 3
  2. aprocitentanphase 3
50%

Simcere Pharmaceutical Group: 5 of its 16 programs at phase 3

  1. SIM0270phase 3
  2. suvemcitugphase 3
  3. SIM0811phase 3
  4. tipiracilphase 3
  5. Trifluridinephase 3
31%
Approved, new studies

Idorsia Pharmaceuticals: 1 of its 4 programs at approved, new studies

  1. daridorexantapproved, new study
25%

Simcere Pharmaceutical Group: 1 of its 16 programs at approved, new studies

  1. trilaciclibapproved, new study
6%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Idorsia Pharmaceuticals1 readouts · 0 phase 3·······

Idorsia Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion

  1. ACT-777991phase 2 · Jun 28 · NCT07667569
····
Simcere Pharmaceutical Group2 readouts · 1 phase 3·······

Simcere Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion

  1. SIM0388phase 1 · Jun 0 · NCT07007988

Simcere Pharmaceutical Group, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trilaciclibapproved, new study · Jul 15 · NCT07881705
···
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Idorsia Pharmaceuticals

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Simcere Pharmaceutical Group

New programs 1

  • SIM0518phase 1 · first study · Oct 22 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 1

  • SIM0811phase 3 · Oct 23 · Ischemic Stroke

Study stopped 0

None

Primary completion later 0

None

Where they overlap

No condition where two of them both have programs.

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Idorsia Pharmaceuticals 3 of 4 · Simcere Pharmaceutical Group 7 of 16 programs (9 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.